-
Patent Agency Ranking
公开(公告)号：US20190263798A1
公开(公告)日：2019-08-29
申请号：US16407300
申请日：2019-05-09
Inventor： John David HARLING , Ian Edward David SMITH
IPC: C07D417/14 , A61K47/66 , A61K47/54 , A61K31/4725 , C07D417/12 , A61K31/519 , C07D487/04
Abstract: A selective IAP binder together with a linker moiety.
-
公开(公告)号：US20180134688A1
公开(公告)日：2018-05-17
申请号：US15568025
申请日：2016-04-20
Inventor： Linda N. CASILLAS , John David HARLING , Afjal Hussain MIAH , Mark David RACKHAM , Ian Edward David SMITH
IPC: C07D403/14 , C07D401/14 , C07D487/04 , C07D417/14 , A61P29/00
CPC classification number: C07D403/14 , A61P29/00 , C07D401/14 , C07D417/14 , C07D487/04
Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
-
公开(公告)号：US20210238162A1
公开(公告)日：2021-08-05
申请号：US16062223
申请日：2016-12-15
Inventor： Rodolfo CADILLA , David Norman DEATON , Ashley Paul HANCOCK , Heather HOBBS , Simon Teanby HODGSON , Andrew L. LARKIN , Joelle LE , Paul N. MORTENSON , Daniel J. PRICE , Gordon SAXTY , Lee T. SCHALLER , Christie SCHULTE , Ian Edward David SMITH , Stephen Andrew THOMSON , Joseph Wendell WILSON
IPC: C07D401/14 , C07D401/12 , C07D215/54 , C07D417/12 , C07D405/12 , C07D413/12 , C07D413/14 , C07D491/056 , C07D491/048 , A61P21/00 , A61P11/06
Abstract: The present invention relates to compounds of Formula (XI): wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) inhibitors and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
-
公开(公告)号：US20190382381A1
公开(公告)日：2019-12-19
申请号：US16547734
申请日：2019-08-22
Inventor： Linda N. CASILLAS , John David HARLING , Afjal Hussain MIAH , Mark David RACKHAM , Ian Edward David SMITH
IPC: C07D403/14 , A61P29/00 , C07D487/04 , C07D417/14 , C07D401/14
Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
-
公开(公告)号：US20180118733A1
公开(公告)日：2018-05-03
申请号：US15568006
申请日：2016-04-20
Inventor： John David HARLING , Ian Edward David SMITH
IPC: C07D417/14 , C07D417/12 , C07D487/04 , A61K31/4725 , A61K31/519
CPC classification number: C07D417/14 , A61K31/4725 , A61K31/519 , A61K47/545 , A61K47/66 , C07D417/12 , C07D487/04
Abstract: The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of RIP2 kinase, including degrading RIP2 kinase, the treatment of diseases and conditions mediated by the RIP2 kinase, in particular for the treatment of inflammatory diseases or conditions.
-
-
-
-
Search Results
5
records
(took 0.018 seconds)
